Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?

Phillips, Kathryn A.; Deverka, Patricia A.; Hooker, Gillian W.; Douglas, Michael P.

doi:10.1377/hlthaff.2017.1427

Cited by 184 publications

(132 citation statements)

References 11 publications

(14 reference statements)

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…25 The decrease also likely coincides with gaining popularity of multiple-gene panel tests and direct-to-consumer genetic testing (which were not captured in this study). [26][27][28][29] Our findings are consistent with a recent study by Lynch and colleagues of Medicare beneficiaries, which showed that CYP pharmacogenetic tests were the most common tests received by this group in 2013. 30 Likewise, "long-term (current) use of other medication" was the most common diagnosis for CYP pharmacogenetic tests among both Medicare cohorts.…”

Section: Discussionsupporting

confidence: 91%

The landscape of pharmacogenetic testing in a US managed care population

Anderson

Crooks

Kao

et al. 2020

Genetics in Medicine

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

The landscape of pharmacogenetic testing in a US managed care population

Anderson

Crooks

Kao

et al. 2020

Genetics in Medicine

View full text Add to dashboard Cite

“…The use of NGS tests (including multigene panels, whole exome, and whole genome sequencing) has been increasing. (1) However, only a limited number of studies have examined their economic value. (2) Several studies have noted that there are methodological challenges to evaluating NGS tests that may be a barrier to conducting evaluations.…”

Section: Introductionmentioning

confidence: 99%

Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background Clinical use of next-generation sequencing (NGS) tests has been increasing, but few studies have examined their economic value. Several studies have noted that there are methodological challenges to conducting economic evaluations of NGS tests. Objective Our objective was to examine key methodological challenges for conducting economic evaluations of NGS tests, prioritize these challenges for future research, and identify how studies have attempted solutions to address these challenges. Methods We identified challenges for economic evaluations of NGS tests using prior literature and expert judgment of the co-authors. We used a modified Delphi assessment to prioritize challenges, based on importance and probability of resolution. Using a structured literature review and article extraction we then assessed whether published economic evaluations had addressed these challenges. Results We identified 11 challenges for conducting economic evaluations of NGS tests. The experts identified three challenges as the top priorities for future research: complex model structure, timeframe, and type of analysis and comparators used. Of the 15 published studies included in our literature review, four studies described specific solutions relevant to five of the 11 identified challenges. Conclusions Major methodological challenges to economic evaluations of NGS tests remain to be addressed. Our results can be used to guide future research and inform decision-makers on how to prioritize research on the economic assessment of NGS tests

show abstract

“…There are currently more than 70,000 unique genetic testing products on the market and an average of 10 new products are added each day (36). The market for clinical sequencing - which encompasses the use of sequencing tests for diagnosis, risk prediction, therapy selection and monitoring, and screening - is growing at a compound annual rate of 28% (37). …”

Section: Precision Medicine – Where Are We Today?mentioning

confidence: 99%

Precision Medicine: From Science To Value

2018

Self Cite

View full text Add to dashboard Cite

Precision medicine is poised to have an impact on patients, health care delivery systems and research participants in ways that were only imagined 15 years ago when the human genome was first sequenced. While discovery using genome-based technologies has accelerated, these have only begun to be adopted into clinical medicine. Here we define precision medicine and the stakeholder ecosystem required to enable its integration into research and health care. We explore the intersection of data science, analytics and precision medicine in creating a learning health system that carries out research in the context of clinical care and at the same time optimizes the tools and information used to delivery improved patient outcomes. We provide examples of real world impact, and conclude with a policy and economic agenda that will be necessary for the adoption of this new paradigm of health care both in the United States and globally.

show abstract

Genetic Test Availability And Spending: Where Are We Now? Where Are We Going?

Cited by 184 publications

References 11 publications

The landscape of pharmacogenetic testing in a US managed care population

The landscape of pharmacogenetic testing in a US managed care population

Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions

Precision Medicine: From Science To Value

Contact Info

Product

Resources

About